Survodutide, a Dual GLP-1/Glucagon Agonist, Improves Beta-Cell Function and Insulin Sensitivity Beyond Weight Loss

Effective management of Type 2 Diabetes (T2D) and obesity remains a significant challenge, often requiring multi-faceted approaches. Current therapies, while beneficial, frequently fall short in comprehensively addressing the complex interplay of insulin resistance, beta-cell dysfunction, and hyperglucagonemia. Single-receptor agonists, such as GLP-1 analogs, have shown efficacy but may not fully optimize metabolic health. Dual agonists targeting both the GLP-1R and glucagon receptor offer a promising strategy to leverage complementary mechanisms, potentially enhancing glucose homeostasis and energy metabolism beyond what single agents can achieve, by simultaneously improving insulin secretion, suppressing glucagon, and promoting weight loss.

This post hoc analysis synthesized data from two phase 2 trials. Trial 1404-0002 randomized 413 participants with Type 2 Diabetes on metformin to receive Survodutide, placebo, or semaglutide for 16 weeks. Trial 1404-0036 randomized 387 participants with overweight/obesity and normoglycaemia to Survodutide or placebo for 46 weeks. Researchers used mixed models for repeated measures and regression analysis to assess biomarker responses and the impact of bodyweight changes on outcomes. The primary endpoints included changes in HOMA-β (beta-cell function), HOMA-IR (insulin sensitivity), and various glucose biomarkers.

In trial 1404-0002 (T2D population), Survodutide was associated with significant and rapid increases in HOMA-β versus placebo, alongside significant decreases in HOMA-IR, glucagon, and fasting plasma glucose (FPG). No significant changes were observed in high-molecular-weight (HMW) adiponectin, C-peptide, or fasting insulin levels in this cohort. In trial 1404-0036 (overweight/obesity, normoglycaemic), HOMA-β showed no significant change with Survodutide versus placebo, likely due to the participants' baseline normoglycaemia. However, Survodutide significantly decreased HOMA-IR, glucagon, C-peptide, fasting insulin, and FPG versus placebo, and significantly increased HMW adiponectin.

Combining all Survodutide dose groups for each trial, absolute change in bodyweight from baseline explained the largest proportion of total variability in changes from baseline in fasting insulin and HOMA-IR. Crucially, it did not explain other observed changes, suggesting metabolic benefits largely independent of weight loss.